Peapack-Gladstone Financial Corp’s BioMarin Pharmaceuticals BMRN Stock Holding History

Peapack-Gladstone Financial Corp’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,600	Closed	-$220K	–	678
2022 Q3	$220K	Sell	2,600 -150	-5%	-$13.4K	﹤0.01%	606
2022 Q2	$228K	Sell	2,750 -2,350	-46%	-$187K	0.01%	568
2022 Q1	$393K	Sell	5,100 -200	-4%	-$16.7K	0.01%	509
2021 Q4	$468K	Buy	5,300 +270	+5%	+$22.3K	0.01%	481
2021 Q3	$388K	Buy	5,030 +1,150	+30%	+$90.7K	0.01%	506
2021 Q2	$324K	Buy	3,880 +600	+18%	+$47.6K	0.01%	498
2021 Q1	$247K	Buy	+3,280	New	+$268K	0.01%	523

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Peapack-Gladstone Financial Corp's BMRN Position: Q4 2022 in Review

Peapack-Gladstone Financial Corp sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2022, closing a stake of 2,600 shares — an estimated $220K sold.

Peapack-Gladstone Financial Corp first reported a position in BMRN in Q1 2021 and held it in 7 quarters. The position peaked at $468K in Q4 2021. 580 funds tracked by Wall St. Rank hold BMRN as of Q4 2022.

Peapack-Gladstone Financial Corp reported no remaining BioMarin Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Peapack-Gladstone Financial Corp sold 2,600 BioMarin Pharmaceuticals shares in Q4 2022, an estimated $220K.
Peapack-Gladstone Financial Corp first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 7 quarters.
Peapack-Gladstone Financial Corp's BioMarin Pharmaceuticals position peaked at $468K in Q4 2021.
580 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2022.

Based on Peapack-Gladstone Financial Corp's 13F filing for Q4 2022, filed 14 Feb 2023.